HOUSTON, Oct. 3, 2019 /PRNewswire/ -- Soliton, Inc.,
(NASDAQ: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology licensed
from The University of Texas on behalf
of the MD Anderson Cancer Center ("MD Anderson"), today announced
that their article entitled, "Increased Tattoo Fading in a
Single Laser Tattoo Removal Session Enabled By a Rapid Acoustic
Pulse Device: A Prospective Clinical Trial," will be
published in the next issue of "Lasers in Surgery and Medicine"
("LSM"). The article was selected as and will subsequently be
featured by LSM as the Editors Choice paper.
The article, which will be included in the September journal,
reviews the clinical trial that was the basis of the submission of
the 510(k) application which was cleared by the FDA in May of
2019. The article can be viewed online via the following
link:
https://onlinelibrary.wiley.com/doi/full/10.1002/lsm.23163
"We are truly pleased to have our article published in the
'Lasers in Surgery and Medicine' journal," commented Dr.
Chris Capelli, President and CEO of
Soliton, "given the high value Soliton places on developing its
products with a foundation of real science. Publication in
this journal is true validation of our technology and trial results
and selection by the editors for the 'Editor's Choice' paper is
even more gratifying."
Join our more than 200K fans here
to follow the Company: https://soly-investors.com
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first FDA cleared commercial product will use rapid
pulses of acoustic shockwaves as an accessory to lasers for the
removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in
bringing the Rapid Acoustic Pulse ("RAP") device to the market. The
Company believes this "Soliton" method has the potential to lower
tattoo removal costs for patients, while increasing profitability
to practitioners, compared to current laser removal methods.
Soliton is investigating potential additional capabilities of the
RAP technology in preclinical testing, including the potential to
assist existing fat reduction technology in the reduction of fat as
well as improving the appearance of cellulite by creating
mechanical stress at the cellular level and inducing significant
collagen growth.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release and in the article linked
to in this release are forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995, which involve risks and
uncertainties. These statements relate to future events, future
expectations, plans and prospects. Although Soliton believes that
the expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. Soliton has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under in our SEC filings,
including under the heading "Item 1A. Risk Factors" in the Form
10-K for year ended December 31, 2018
we filed with the SEC and updated from time to time in our Form
10-Q filings and in our other public filings with the SEC. Any
forward-looking statements contained in this release and in the
article linked to in this release speak only as of its date.
Soliton undertakes no obligation to update any forward-looking
statements contained in this release and in the article linked to
in this release to reflect events or circumstances occurring after
its date or to reflect the occurrence of unanticipated events.
View original
content:http://www.prnewswire.com/news-releases/soliton-announces-tattoo-technology-article-published-in-medical-journal-and-selected-as-editors-choice-300930327.html
SOURCE Soliton, Inc.